GPVI interplay with fibrin(ogen) in thrombosis.
Fiche publication
Date publication
mars 2023
Journal
Journal of thrombosis and haemostasis : JTH
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MANGIN Pierre
Tous les auteurs :
Mangin PH, Gardiner EE, Ariëns RAS, Jandrot-Perrus M
Lien Pubmed
Résumé
Platelets play a central role in arrest of bleeding. The ability of platelets to engage with extracellular matrix proteins of the subendothelium has long been recognised as a pivotal platelet attribute, underpinning adequate haemostasis. The propensity of platelets to rapidly bind and functionally respond to collagen was one of the earliest documented events in platelet biology. The receptor primarily responsible for mediating platelet/collagen responses was identified as glycoprotein (GP) VI and successfully cloned in 1999. Since that time, this receptor has held the attention of many research groups and through these efforts, we now have an excellent understanding of the roles of GPVI as a platelet- and megakaryocyte-specific adheso-signalling receptor in platelet biology. GPVI is considered as a viable antithrombotic target, as data obtained from groups across the world is consistent with GPVI being less involved in physiological haemostatic processes but participating in arterial thrombosis. This review will highlight the key aspects of GPVI contributions to platelet biology and concentrate on the interaction with recently identified ligands, with a focus on fibrin and fibrinogen, discussing the role of these interactions in the growth and stability of thrombi. We will also discuss important therapeutic developments that target GPVI with the goal to modulate platelet function whilst minimising bleeding outcomes.
Référence
J Thromb Haemost. 2023 03 27;: